Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Among authors: sasaki y. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article.
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y. Nakatsumi H, et al. Among authors: sasaki y. Int J Cancer. 2024 Dec 15;155(12):2223-2231. doi: 10.1002/ijc.35116. Epub 2024 Aug 14. Int J Cancer. 2024. PMID: 39143041 Clinical Trial.
Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Takahashi N, et al. Among authors: sasaki y. Cancer Sci. 2015 May;106(5):604-10. doi: 10.1111/cas.12642. Epub 2015 Apr 29. Cancer Sci. 2015. PMID: 25707609 Free PMC article. Clinical Trial.
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.
Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. Takahashi N, et al. Among authors: sasaki y. Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. doi: 10.1007/s00280-016-3111-x. Epub 2016 Jul 20. Cancer Chemother Pharmacol. 2016. PMID: 27438067 Clinical Trial.
6,164 results